Adalimumab reduces the signs and symptoms of Ankylosing Spondylitis (AS) for up to three years of treatment, research reveals.
The data, which come from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) Phase III clinical trial, were presented this weekend at the European League Against Rheumatism (EULAR) annual meeting in Paris.
The release of the trial results follow recent guidance by the National Institute for Health and Clinical Excellence (NICE), in May 2008, which recommended the use of adalimumab for the treatment of severe active ankylosing spondylitis.
The guidance marked the first time that NICE reviewed anti-tumour necrosis factor therapies for the treatment of AS.
Lead investigator Paul Wordsworth said: “AS is a painful and progressive condition which requires effective therapies that relieve back and joint pain.
“The results of this three-year study will come as good news to patients as they add to the evidence of HUMIRA’s efficacy in reducing the signs and symptoms of AS.”